Related Experiment Videos
Pimobendan in heart failure therapy--a silver bullet?
Sonya G Gordon1, Matthew W Miller, Ashley B Saunders
1Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Science, Texas A&M University, College Station, Texas 77843-4474, USA.
Journal of the American Animal Hospital Association
|March 11, 2006
Summary
Pimobendan improves quality of life for dogs with congestive heart failure (CHF) from dilated cardiomyopathy (DCM) or valvular disease. This safe medication, when combined with other therapies, reduces mortality in dogs with DCM-related CHF.
Area of Science:
- Veterinary Cardiology
- Pharmacology
- Canine Health
Background:
- Congestive heart failure (CHF) is a significant concern in canine cardiology.
- Dilated cardiomyopathy (DCM) and chronic degenerative valvular disease are common causes of CHF in dogs.
- Effective management strategies for canine CHF are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of pimobendan in dogs with CHF.
- To assess the impact of pimobendan on quality of life and mortality in dogs with CHF secondary to DCM or chronic valvular disease.
- To determine the benefits of pimobendan when used as adjunctive therapy.
Main Methods:
- Review of available clinical data on pimobendan use in dogs.
- Analysis of studies involving pimobendan in combination with conventional CHF therapies (e.g., furosemide, ACE inhibitors, digoxin).
- Assessment of quality of life indicators and mortality rates in treated canine patients.
Main Results:
- Pimobendan is safe and well-tolerated in dogs with CHF.
- The drug enhances the quality of life for dogs suffering from CHF due to DCM or chronic valvular disease.
- Pimobendan demonstrates a reduction in mortality for canine CHF associated with DCM.
Conclusions:
- Pimobendan is a valuable therapeutic agent for managing canine congestive heart failure.
- Combination therapy including pimobendan offers significant benefits for dogs with DCM and valvular disease.
- Further research is ongoing to fully elucidate pimobendan's effects on mortality in chronic valvular disease.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.